Table 1 Demographic and clinical characteristics of control subjects and COVID-19 patients (n.a., not applicable)
| Â | Control subjects (negative SARS-CoV-2 swab) | COVID-19 patients (positive SARS-CoV-2 swab) | ||
|---|---|---|---|---|
n | 9 | 21 | ||
Sex assigned at birth (Female/Male) | 5/4 | 10/11 | ||
Age at recruitment (mean ± SD) | 70.7 ± 20.7 | 67.3 ± 17.1 | ||
Symptoms n (%) | Pneumonia | 0 (0) | 12 (57.1) | |
Respiratory failure | 1 (11.1) | 9 (42.9) | ||
Gastrointestinal | 0 (0) | 7 (33.3) | ||
Others | 8 (88.9) | 0 (0) | ||
Discharge type n (%) | Transferred | n.a. | 13 (61.9) | |
Ordinary | n.a. | 5 (23.8) | ||
Deceased | n.a. | 3 (14.3) | ||
Early treatment (first 2–3 days post admission) n (%) | Azithromycin (AZ) | n.a. | 3 (14.3) | |
Hydroxychloroquine (HCQ) | n.a. | 5 (23.8) | ||
AZ + HCQ | n.a. | 5 (23.8) | ||
Other | n.a. | 8 (38.1) | ||